Loading
A phase 2 trial of EMB-01 1600 mg administered once weekly throughout the study in colorectal cancer, run by Shanghai EpimAb Biotherapeutics Co., Ltd., now recruiting.
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients is a phase 2 interventional study registered as NCT07314294 by Shanghai EpimAb Biotherapeutics Co., Ltd., with 54 participants planned, started 2025-12-18 and due to reach its primary completion in 2027-12-30. Interventions recorded: EMB-01 1600 mg administered once weekly throughout the study and EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.